Effects of rosiglitazone and interactions with growth-regulating factors in ventricular cell hypertrophy

European Journal of Pharmacology

Volumn 508, Issue 1-3, 2005, Pages 69-76

  Bell, David ^a   McDermott, Barbara J ^a  

^a School of Medicine and Dentistry   (United Kingdom)

Author keywords

Cardiac; Diabetes; Hypertrophy; PPAR ; Protein kinase C; Troglitazone

Indexed keywords

CELL PROTEIN; ENDOTHELIN 1; GLUCOSE; GROWTH FACTOR; INSULIN; NORADRENALIN; ROSIGLITAZONE; SOMATOMEDIN C; TROGLITAZONE;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HEART MUSCLE CELL; HEART VENTRICLE; HYPERTROPHY; MALE; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CULTURE MEDIA; CULTURE MEDIA, SERUM-FREE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENDOTHELIN-1; GLUCOSE; HEART VENTRICLES; HYPERTROPHY; INSULIN; INSULIN-LIKE GROWTH FACTOR I; ISOPROTERENOL; MALE; MYOCYTES, CARDIAC; NOREPINEPHRINE; PHENYLALANINE; RATS; RATS, SPRAGUE-DAWLEY; TETRADECANOYLPHORBOL ACETATE; THIAZOLIDINEDIONES;

EID: 12844268822     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.12.027     Document Type: Article

References (20)

1. M. Asakawa, H. Takano, T. Nagai, H. Uozumi, H. Hasegawa, N. Kubota, T. Saito, Y. Masuda, T. Kadowaki, and I. Komuro Peroxisome proliferators-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and vivo Circulation 105 2002 1152 1154
2. M. Bahr, M. Spelleken, M. Bock, M. von Holtey, R. Kiehn, and J. Eckel Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes Diabetologia 39 1996 766 774
3. D. Bell, and B.J. McDermott Troglitazone does not initiate ventricular cardiomyocyte hypertrophy in vitro but can sensitise cardiomyocytes to the hypertrophic effects of serum growth factors Eur. J. Pharmacol. 390 2000 237 244
4. H.S. Camp, O. Li, S.C. Wise, Y.H. Hong, C.L. Frankowski, X. Shen, R. Vanbogelen, and T. Leff Differential activation of PPARγ by troglitazone and rosiglitazone Diabetes 49 2000 539 547
5. M.N. Ghazzi, J.E. Perez, T.K. Antonucci, J.H. Driscoll, S.M. Haung, and B.W. Faja The Troglitazone Study Group R.W. Whitcomb Cardiac and glycaemic benefits of troglitazone treatment in NIDDM Diabetes 46 1997 433 439
6. A.J. Glide, and M. VanBilsen Peroxisome proliferators-activated receptors (PPARs): regulators of gene expression in heart and skeletal muscle Acta Physiol. Scand. 178 2003 425 434
7. R.K. Gupta, and B.A. Wittenberg Nuclear magnetic resonance studies of free calcium in heart cells Biophys. J. 65 1993 2547 2558
8. K.D. Hopkins Heart mass not altered by troglitazone Lancet 349 1997 781
9. S.L. Jacobson, and H.M. Piper Cell cultures of adult cardiomyocytes as models of the myocardium J. Mol. Cell. Cardiol. 18 1986 439 448
10. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Wilson, and S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ) J. Biol. Chem. 270 1995 12953 12956
11. A.M. Lennon, M. Ramauge, A. Dessouroux, and M. Pierre MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy-delta 12-14 prostaglandin J2 and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxygenated species J. Biol. Chem. 277 2002 29681 29685
12. R. Mayfield, D. McLean, D. Crook, D.P. Buist, and C. Gopinath CS-045 toxicity to the Cynomolgus monkeys by repeated oral administration for 52 weeks J. Clin. Ther. Med. 9 Suppl. 3 1993 317 341
13. D.M. Mullan, D. Bell, E.J. Kelso, and B.J. McDermott Involvement of ETA and ETB receptors in the hypertrophic effects of endothelin-1 in adult rabbit ventricular cardiomyocytes J. Cardiovasc. Pharmacol. 29 1997 350 359
14. A. Pinson, K.D. Schluter, X.J. Zhou, P. Schwartz, G. Kessler-Icekson, and H.M. Piper Alpha and beta adrenergic stimulation in cultured adult ventricular cardiomyocytes J. Mol. Cell. Cardiol. 25 1993 477 490
15. K.D. Schluter, B.C. Millar, B.J. McDermott, and H.M. Piper Regulation of protein synthesis and degradation in adult ventricular cardiomyocytes Am. J. Physiol. 38 1995 C1347 C1355
16. S.F. Steinberg, M. Goldberg, and V.O. Rybin Protein kinase C isoform diversity in the heart J. Mol. Cell. Cardiol. 27 1995 141 153
17. T.W. Stephens, J.A. Bergman, J.M. Bue-Valleskey, R.D. DiMarchi, L.J. Slieker, F.C. Tinsley, and G.D. Williams Thiazolidinedione induced cardiac biochemical changes and increased IGF-1 action on cardiomyocytes Diabetologia 38 1995 A200
18. M. St. John Sutton, M. Rendell, P. Dandona For the Rosiglitazone Clinical Trials Study Group A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycaemic control in patients with Type 2 diabetes Diabetes Care 25 2002 2058 2064
19. H.W. Vliegen, A.V.G. Bruschke, and A. Van der Laarse Different response of cellular DNA content to cardiac hypertrophy in human and rat heart myocytes Comp. Biochem. Physiol. 95 1990 109 114
20. X.J. Zhou, K.D. Schluter, and H.M. Piper Hypertrophic responsiveness to beta 2-adrenoceptor stimulation on adult ventricular cardiomyocytes Mol. Cell. Biochem. 163-164 1996 211 216